Prelude Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 12, 2024
PRLD$3.76+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity (Unaudited)
STATEMENTS OF CHANGES INSTOCKHOLDERS’ EQUITY
| Voting common stock · Non-voting commonstock · Additional paid-in · Accumulated other comprehensive · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| (in thousands, except shares) | Shares | Amount | Shares | Amount | capital | loss | deficit | Total |
| Balance at January 1, 2024 | 42,063,995 | $4 | 12,850,259 | $1 | $693,252 | $223 | $(456,390) | $237,090 |
| Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 4,285 shares withheld for employee taxes | 7,510 | — | — | — | (14) | — | — | (14) |
| Unrealized loss on marketable securities, net of tax | — | — | — | — | — | (458) | — | (458) |
| Stock-based compensation expense | — | — | — | — | 5,547 | — | — | 5,547 |
| Net loss | — | — | — | — | — | — | (31,431) | (31,431) |
| Balance at March 31, 2024 | 42,071,505 | $4 | 12,850,259 | $1 | $698,785 | $(235) | $(487,821) | $210,734 |
| Issuance of common stock upon exercise of stock options & vesting of RSU's, net of 3,722 shares withheld for employee taxes | 7,803 | — | — | — | (16) | — | — | (16) |
| Issuance of common stock under ESPP | 78,916 | — | — | — | 255 | — | — | 255 |
| Unrealized loss on marketable securities, net of tax | — | — | — | — | — | (55) | — | (55) |
| Stock-based compensation expense | — | — | — | — | 6,098 | — | — | 6,098 |
| Net loss | — | — | — | — | — | — | (34,740) | (34,740) |
| Balance at June 30, 2024 | 42,158,224 | $4 | 12,850,259 | $1 | $705,122 | $(290) | $(522,561) | $182,276 |
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (CONTINUED)
| Voting common stock · Non-voting common stock · Additional paid-in · Accumulated other comprehensive · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| (in thousands, except shares) | Shares | Amount | Shares | Amount | capital | loss | deficit | Total |
| Balance at January 1, 2023 | 36,496,994 | $4 | 11,402,037 | $1 | $531,682 | $(1,692) | $(334,558) | $195,437 |
| Issuance of common stock upon exercise of stock options & vesting of RSUs | 17,224 | — | — | — | 28 | — | — | 28 |
| Unrealized gain on marketable securities, net of tax | — | — | — | — | — | 1,294 | — | 1,294 |
| Stock-based compensation expense | — | — | — | — | 6,256 | — | — | 6,256 |
| Net loss | — | — | — | — | — | — | (27,718) | (27,718) |
| Balance at March 31, 2023 | 36,514,218 | $4 | 11,402,037 | $1 | $537,966 | $(398) | $(362,276) | $175,297 |
| Issuance of common stock and prefunded warrants, net of issuance costs of $2.6 million | 5,312,978 | — | 1,448,222 | — | 110,423 | — | — | 110,423 |
| Issuance of common stock upon exercise of stock options & vesting of RSU's | 40,461 | — | — | — | 3 | — | — | 3 |
| Issuance of common stock under ESPP | 90,799 | — | — | — | 348 | — | — | 348 |
| Unrealized loss on marketable securities, net of tax | — | — | — | — | — | (313) | — | (313) |
| Stock-based compensation expense | — | — | — | — | 6,733 | — | — | 6,733 |
| Net loss | — | — | — | — | — | — | (30,431) | (30,431) |
| Balance at June 30, 2023 | 41,958,456 | $4 | 12,850,259 | $1 | $655,473 | $(711) | $(392,707) | $262,060 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.